OpenAI's Bold Move: Profit Sharing in Drug

Alright, folks, grab your popcorn because OpenAI just stirred the pot big time. They're eyeing a slice of the profits from AI-assisted drug discoveries made by their customers. Cue the Twitter outrage. But before we all jump to conclusions, let's peel back the layers of this tech-on-steroids story.

The Proposal

Imagine you're a pharma company, your lab coats are crisp, and you're knee-deep in drug discovery. You've got a subscription to OpenAI's ChatGPT, and it's crunching data like a boss—analyzing research papers, suggesting molecular structures, and predicting protein interactions. Suddenly, boom! You land on a billion-dollar drug. OpenAI's saying, "Hey, we'd like a piece of that pie," because their tech helped you get there. "OpenAI would take a profit-sharing stake in the financial upside it creates for its customers," the video lays out.

This isn't just your typical software fee. OpenAI wants a percentage of the profits, essentially turning their tech into a business partner. But here's where it gets as sticky as a melted popsicle in July: How do you prove the AI was the real MVP in the discovery process?

The Outrage

The backlash isn't just about OpenAI’s audacity. It's about the principle. Critics are pointing fingers, calling it a double standard. OpenAI used copyrighted data to train their models without paying a dime—now they're asking for a cut when their clients find success using those models. It's like Microsoft demanding royalties for every novel written in Word. Cue the confusion and eye-rolls.

The Competition

OpenAI isn't sailing these waters alone. Isomorphic Labs, a Google DeepMind brainchild, is already playing this game. They've got deals with pharma giants like Eli Lilly and Novartis, securing upfront and milestone payments, and royalties if drugs hit the jackpot. Their approach is different from OpenAI's: they were built for drug discovery from day one. OpenAI, on the other hand, is trying to retrofit their existing AI tool into this niche.

The Big "What If?"

Here's the existential twist: OpenAI's proposal raises juicy questions. Who really owns the value created in the digital economy? If AI assists in discovery, does it deserve a share of the spoils? And what happens when the tech that was supposed to democratize access starts demanding a fee at the door?

The Future

So, will OpenAI’s master plan revolutionize pharma or nosedive into legal chaos? That's the billion-dollar question. With competitors like Isomorphic Labs already entrenched and pharma companies wary of sharing profits, OpenAI's path isn't exactly smooth sailing. But hey, if they pull it off, it might just set a precedent for AI-driven industries everywhere.

In the end, the industry's future might hinge on OpenAI's ability to finesse this proposal. Will they pivot and create a dedicated drug discovery subsidiary like Isomorphic Labs? Or will they find a way to integrate their existing tool into the pharma world seamlessly? Only time will tell. And trust me, the stakes have never been higher.

By Zara Chen